Cargando…
Integration of Different “-omics” Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells
Hematological malignancies frequently have a poor prognosis and often remain incurable. Drug resistance, severe side effects, and relapse are major problems of currently used drugs, and new candidate compounds are required for improvement of therapy success. The naphthoquinone shikonin derived from...
Autores principales: | Wiench, Benjamin, Chen, Yet-Ran, Paulsen, Malte, Hamm, Rebecca, Schröder, Sven, Yang, Ning-Sun, Efferth, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703888/ https://www.ncbi.nlm.nih.gov/pubmed/23861714 http://dx.doi.org/10.1155/2013/818709 |
Ejemplares similares
-
Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells
por: Wiench, Benjamin, et al.
Publicado: (2012) -
Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
por: Markowitsch, Sascha D., et al.
Publicado: (2022) -
β-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling
por: LU, DAN, et al.
Publicado: (2015) -
β-Hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling
por: Lu, Dan, et al.
Publicado: (2021) -
Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin
por: Ni, Fan, et al.
Publicado: (2018)